We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
+1.9%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$3.17M
AUM Growth
+$561K
Cap. Flow
+$147M
Cap. Flow %
4,647.33%
Top 10 Hldgs %
63.1%
Holding
323
New
68
Increased
74
Reduced
74
Closed
84

Top Buys

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$37.9M
2
ACAD icon
Acadia Pharmaceuticals
ACAD
+$24.5M
3
MRK icon
Merck
MRK
+$12.3M
4
GILD icon
Gilead Sciences
GILD
+$11.7M
5
ACHN
Achillion Pharmaceuticals
ACHN
+$11.6M

Top Sells

Rank Stock Value
1
LRMR icon
Larimar Therapeutics
LRMR
+$4.64M
2
OCUL icon
Ocular Therapeutix
OCUL
+$3.33M
3
ACGN
Aceragen Inc
ACGN
+$2.48M
4
ASPX
AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
+$2.06M
5
PRQR icon
ProQR Therapeutics
PRQR
+$1.95M

Sector Composition

Rank Sector Weight
1 Healthcare 9.16%
2 Energy 0.42%
3 Industrials 0.14%
4 Consumer Staples 0.11%
5 Technology 0.09%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SGMO
26
CALL
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$15.5K 0.49%
10,168
+156
+2% +$1.89K
BMY icon
27
PUT
Bristol-Myers Squibb
BMY
$130B
$13.9K 0.44%
2,359
– –
A icon
28
CALL
Agilent Technologies
A
$39.7B
$13.7K 0.43%
3,337
-3,696
-53% -$149K
AUXL
29
CALL
DELISTED
AUXILIUM PHARAMCEUTICALS INC
AUXL
$13.6K 0.43%
3,964
+117
+3% +$3.82K
AZN icon
30
AstraZeneca
AZN
$267B
$13.5K 0.43%
192,055
-23,268
-11% -$1.67M
IOC
31
DELISTED
Interoil Corporation
IOC
$13.2K 0.42%
270,330
+46,351
+21% +$2.48M
BLUE
32
CALL
DELISTED
bluebird bio
BLUE
$12.6K 0.4%
106
+29
+38% +$19.4K
ACHN
33
DELISTED
Achillion Pharmaceuticals
ACHN
$12.3K 0.39%
1,004,187
+946,216
+1,632% +$11.6M
MRK icon
34
Merck
MRK
$326B
$12K 0.38%
+221,264
New +$12.3M
BIIB icon
35
PUT
Biogen
BIIB
$30.4B
$11.1K 0.35%
327
– –
GILD icon
36
Gilead Sciences
GILD
$167B
$10.7K 0.34%
+113,260
New +$11.7M
MNKD icon
37
PUT
MannKind Corp
MNKD
$1.21B
$9.84K 0.31%
3,773
-1,337
-26% -$37.8K
SRPT icon
38
CALL
Sarepta Therapeutics
SRPT
$1.63B
$9.51K 0.3%
6,572
+2,998
+84% +$50.8K
AMGN icon
39
CALL
Amgen
AMGN
$212B
$9.24K 0.29%
580
-523
-47% -$81.5K
TENX icon
40
Tenax Therapeutics
TENX
$419M
$9.03K 0.29%
73
-15
-17% -$1.82M
CBST
41
CALL
DELISTED
CUBIST PHARMACEUTICALS INC
CBST
$8.79K 0.28%
+873
New +$67.9K
DHR icon
42
CALL
Danaher
DHR
$140B
$8.57K 0.27%
+1,488
New +$80.7K
DHR icon
43
PUT
Danaher
DHR
$140B
$8.57K 0.27%
+1,488
New +$80.7K
TEVA icon
44
PUT
Teva Pharmaceuticals
TEVA
$36.9B
$8.52K 0.27%
1,481
+65
+5% +$3.62K
CYH icon
45
PUT
Community Health Systems
CYH
$393M
$8.5K 0.27%
+1,908
New +$81.6K
MRK icon
46
CALL
Merck
MRK
$326B
$8.39K 0.27%
1,548
-5,075
-77% -$283K
MBLY
47
PUT
DELISTED
Mobileye N.V.
MBLY
$8.35K 0.26%
+2,058
New +$96.6K
BMRN icon
48
CALL
BioMarin Pharmaceuticals
BMRN
$12B
$8.34K 0.26%
+923
New +$76.8K
CARM
49
DELISTED
Carisma Therapeutics
CARM
$8.29K 0.26%
34,874
+33,874
+3,387% +$7.6M
PBYI icon
50
PUT
Puma Biotechnology
PBYI
$406M
$7.87K 0.25%
416
+182
+78% +$40.4K
1
2
3 4 5

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q4 2014 Portfolio in Review

As of Q4 2014, Sabby Management held 323 positions worth $3.17M, up 22% from $2.6M the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Sabby Management deployed $147M of net new capital in Q4 2014, opening 68 new positions and adding to 74 existing holdings. Its largest new stake was Pfizer: 1,322,658 shares worth $39.1K.

By sector, the portfolio is most concentrated in Healthcare at 9.2% of assets, up from 6.3% a quarter earlier, followed by Energy and Industrials.

On the sell side, the largest reduction was Larimar Therapeutics, an estimated $4.64M trimmed.

  • Sabby Management's largest Q4 2014 buy was Pfizer: 1,322,658 shares worth $39.1K.
  • Sabby Management added most to Achillion Pharmaceuticals in Q4 2014, an estimated $11.6M increase.
  • Sabby Management's biggest Q4 2014 reduction was Larimar Therapeutics, cutting an estimated $4.64M.
  • Sabby Management fully exited Aceragen Inc in Q4 2014, selling an estimated $2.48M.
  • Sabby Management's ten largest holdings make up 63% of its $3.17M portfolio in Q4 2014.
  • Sabby Management opened 68 new positions and closed 84 in Q4 2014.
  • Sabby Management's portfolio value rose 22% quarter-over-quarter to $3.17M.

Based on Sabby Management's 13F filing for Q4 2014, filed 17 Feb 2015.